➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson

Last Updated: September 24, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,682,061

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,682,061 protect, and when does it expire?

Patent 9,682,061 protects ORBACTIV and is included in one NDA.

This patent has seven patent family members in seven countries.

Summary for Patent: 9,682,061
Title:Methods of treating bacterial infections using oritavancin
Abstract: The present invention is directed to methods of treating a bacterial infection in a subject through the administration of a therapeutically effective amount of a glycopeptide antibiotic to a subject having a bacterial infection. The effective amount of the glycopeptide antibiotic that is administered to the subject provides a fraction of the glycopeptide antibiotic administered to the subject bound to serum proteins within the subject and within a selected range.
Inventor(s): Lehoux; Dario (Terrebonne, CA), Parr, Jr.; Thomas (Indianapolis, IN), Moeck; Gregory (St. Laurent, CA)
Assignee: THE MEDICINES COMPANY (Parsippany, NJ)
Application Number:12/740,571
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Drugs Protected by US Patent 9,682,061

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Melinta Therap ORBACTIV oritavancin diphosphate POWDER;INTRAVENOUS 206334-001 Aug 6, 2014 RX Yes Yes   Start Trial   Start Trial TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,682,061

PCT Information
PCT FiledApril 26, 2010PCT Application Number:PCT/US2010/032441
PCT Publication Date:November 11, 2010PCT Publication Number: WO2010/129233

International Family Members for US Patent 9,682,061

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2010245097   Start Trial
Brazil PI1014767   Start Trial
Canada 2760159   Start Trial
China 102573882   Start Trial
European Patent Office 2424559   Start Trial
Japan 2012525391   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.